| 000 | 01578 a2200421 4500 | ||
|---|---|---|---|
| 005 | 20250518061304.0 | ||
| 264 | 0 | _c20201204 | |
| 008 | 202012s 0 0 eng d | ||
| 022 | _a1618-7601 | ||
| 024 | 7 |
_a10.1007/s10198-019-01110-w _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aSvedbom, Axel | |
| 245 | 0 | 0 |
_aThe value of persistence in treatment with subcutaneous TNF-alpha inhibitors for ankylosing spondylitis. _h[electronic resource] |
| 260 |
_bThe European journal of health economics : HEPAC : health economics in prevention and care _cFeb 2020 |
||
| 300 |
_a45-54 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 | _aCost-Benefit Analysis |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aInjections, Subcutaneous |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMarkov Chains |
| 650 | 0 | 4 | _aModels, Econometric |
| 650 | 0 | 4 | _aQuality-Adjusted Life Years |
| 650 | 0 | 4 | _aSeverity of Illness Index |
| 650 | 0 | 4 |
_aSpondylitis, Ankylosing _xdrug therapy |
| 650 | 0 | 4 |
_aTumor Necrosis Factor Inhibitors _xadministration & dosage |
| 650 | 0 | 4 | _aUnited Kingdom |
| 650 | 0 | 4 | _aAssessment of Medication Adherence |
| 700 | 1 | _aDalén, Johan | |
| 700 | 1 | _aIvergård, Moa | |
| 700 | 1 | _aBorse, Rebekah H | |
| 700 | 1 | _aBlack, Christopher M | |
| 700 | 1 | _aLuttropp, Karin | |
| 700 | 1 | _aKachroo, Sumesh | |
| 773 | 0 |
_tThe European journal of health economics : HEPAC : health economics in prevention and care _gvol. 21 _gno. 1 _gp. 45-54 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1007/s10198-019-01110-w _zAvailable from publisher's website |
| 999 |
_c30113321 _d30113321 |
||